Abstract 187P
Background
Camrelizumab, an anti-PD-1 inhibitor, has been approved either alone or in combination in China for advanced esophageal squamous cell carcinoma. We conducted an IPD analysis of 987 patients to evaluate the effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer.
Methods
The IPD were pooled from the three independent, large-scale, prospective multicenter observational cohort studies (ESCORT-RWS/NCT04616040, NOAH-EC201/ChiCTR1900027275, and ChiCTR2000039499). All patients aged ≥18 years and had received at least one dose of camrelizumab for advanced esophageal cancer were included for analyses. The study outcomes were patterns of camrelizumab use, progression-free survival (PFS), overall survival (OS), and safety in the overall population and specific subgroups of patients that were underrepresented in clinical trials (aged ≥75 years or with ECOG performance status [PS] ≥2).
Results
Among 987 patients pooled from 91 centers across 20 provinces in China, 450 (45.6%) received camrelizumab in the first line, 398 (40.3%) in the second line, and 139 (14.1%) in the third line or later. Camrelizumab combined with chemotherapy (69.7%) was most commonly prescribed regardless of line of therapy, primarily with taxanes plus platinum-based chemotherapy. The median OS was 15.5 (95% CI: 12.6, 18.4) in the first line, 12.1 (95% CI: 10.0, 14.7) in the second line, and 10.9 (95% CI: 8.1, 14.5) months in the third line or later. The corresponding PFS was 9.9 (95% CI: 7.4, 14.4), 6.6 (95% CI: 5.1, 8.8), and 5.7 (95% CI: 3.1, 9.6) months, respectively. Patients aged ≥75 years had survival similar to the overall population and those younger in age. Patients with PS ≥ 2 and with camrelizumab in the second line or later had shorter survival than their counterparts with PS of 0 or 1. Overall, 721 (73.0%) patients experienced adverse events, with no new safety signals.
Conclusions
This study provides an overview of camrelizumab use in unselected real-world patients with advanced esophageal cancer. The effectiveness and safety of camrelizumab is generally consistent with that observed in pivotal trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.